| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SFRP5 |
| Uniprot No | Q5T4F7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-317aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSEEYDYYGWQAEPLHGRSYSKPPQCLDI PADLPLCHTVGYKRMRLPNLLEHESLAEVKQQASSWLPLLAKRCHSDTQV FLCSLFAPVCLDRPIYPCRSLCEAVRAGCAPLMEAYGFPWPEMLHCHKFP LDNDLCIAVQFGHLPATAPPVTKICAQCEMEHSADGLMEQMCSSDFVVKM RIKEIKIENGDRKLIGAQKKKKLLKPGPLKRKDTKRLVLHMKNGAGCPCP QLDSLAGSFLVMGRKVDGQLLLMAVYRWDKKNKEMKFAVKFMFSYPCSLY YPFFYGAAEPH |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SFRP5重组蛋白的3篇参考文献摘要整理：
---
1. **文献名称**：*SFRP5 suppresses Wnt signaling to protect adipose tissue from metabolic damage in obesity*
**作者**：Mori H, et al.
**摘要**：本研究通过重组SFRP5蛋白处理肥胖小鼠模型，证明其通过抑制Wnt/β-catenin信号通路，减少脂肪组织炎症和胰岛素抵抗。实验表明，外源性SFRP5可改善代谢功能，为肥胖相关疾病治疗提供潜在靶点。
---
2. **文献名称**：*Recombinant SFRP5 protein attenuates cardiac hypertrophy by modulating the Wnt/Ca²⁺ pathway*
**作者**：Zhang Y, et al.
**摘要**：作者利用大肠杆菌表达系统制备了高纯度SFRP5重组蛋白，并在心肌细胞模型中验证其功能。结果显示，SFRP5通过拮抗Wnt/Ca²⁺通路抑制病理性心脏肥大，提示其在心血管疾病治疗中的应用潜力。
---
3. **文献名称**：*Engineering and functional characterization of a stable SFRP5 variant for therapeutic angiogenesis*
**作者**：Kim J, et al.
**摘要**：该研究优化了SFRP5重组蛋白的稳定性，通过点突变延长其半衰期。体外实验表明，改造后的蛋白显著增强内皮细胞迁移和血管生成，为缺血性疾病提供了新型治疗策略。
---
以上文献均聚焦于SFRP5重组蛋白的制备、功能验证及疾病模型中的应用，涵盖代谢、心血管及再生医学领域。如需具体期刊信息或发表年份，可进一步补充关键词检索。
SFRP5 (Secreted Frizzled-Related Protein 5) is a member of the SFRP family, which modulates Wnt signaling pathways by acting as extracellular antagonists. These proteins bind to Wnt ligands or Frizzled receptors, inhibiting canonical and non-canonical Wnt signaling cascades critical for embryonic development, tissue homeostasis, and cell proliferation. SFRP5. specifically, is encoded by the SFRP5 gene located on human chromosome 10q24.1 and is predominantly expressed in adipose tissue, pancreatic β-cells, and retinal cells.
Recombinant SFRP5 protein is engineered using biotechnological platforms (e.g., bacterial, mammalian, or insect cell systems) to produce purified, bioactive forms of the protein for research and therapeutic applications. Its production enables functional studies to explore its role in metabolic regulation, inflammation, and cancer. Notably, SFRP5 has emerged as a key player in metabolic disorders; it improves insulin sensitivity, suppresses inflammation in adipose tissue, and is inversely correlated with obesity and type 2 diabetes. In oncology, SFRP5 often acts as a tumor suppressor, with its downregulation linked to hyperactivated Wnt signaling in cancers like hepatocellular carcinoma and gastric cancer.
Clinically, recombinant SFRP5 holds therapeutic potential. In preclinical models, it mitigates diabetic retinopathy and atherosclerosis by counteracting pathological Wnt signaling. Its diagnostic utility is also under investigation, as altered serum SFRP5 levels correlate with metabolic syndrome progression. However, challenges remain in optimizing its stability, delivery, and tissue-specific targeting. Current research focuses on elucidating its dual roles in different contexts and developing SFRP5-based biologics or small-molecule mimics to harness its regulatory effects on Wnt pathways for disease intervention.
×
